DD — DuPont de Nemours, Inc.

Sentiment is positive following Q2 2026 results (August 4, 2026): adjusted EPS of $1.88 beat the $1.76 consensus, organic sales grew 4%, management raised full-year adjusted EPS guidance to $7.17-$7.32, and free cash flow conversion hit 127%. Analyst positioning is strongly buy-leaning (24 Buy/16 Hold/1 Sell per the live brief), and the $250M Q3 share repurchase program adds a floor. The lingering NY AG PFAS lawsuit (July 2026) is the main sentiment drag, but it has not displaced the beat-and-raise narrative.

The reported 3-year quarterly series is dominated by a discontinuity, not an organic trend: revenue stepped down from $3.07B in Q3 2025 to $1.69B in Q4 2025 (-45%) as a major business was separated/divested, and total assets fell from $38.0B to $21.6B over the same quarter. The deterministic score's note flags this. Within the continuing business, the trend is inflecting upward: Q1 2026 revenue of $1.68B rose to Q2 2026 revenue of $1.82B (+8% sequentially, +4% organic YoY), GAAP operating margin expanded from 11.1% to 14.1%, and the raised guidance implies H2 2026 revenue of ~$3.66-$3.69B versus $3.50B in H1 - i.e., acceleration. GAAP net income remains noisy from one-time items (Q1 2025 -$589M, Q4 2025 -$126M), but the underlying business is improving, not deteriorating.

Headline multiples are distorted: the TTM P/E of 301.8x and 0.7% TTM net margin reflect one-time charges and discontinued operations, not the ongoing company. On a forward basis, the stock trades at roughly 19.2x the raised 2026 adjusted EPS midpoint of $7.25 - well above DuPont's 5-year average P/E of 14.6x but below high-quality specialty-chemical peers. Price-to-sales of 2.27x TTM versus a 1.46x 5-year average looks rich, though the revenue base is now smaller and higher-margin. Net: fair to modestly rich - the market is paying a premium for the cleaner, lower-debt post-spinoff portfolio.

As of 2026-08-27, the $138.83 price embeds roughly 19x forward adjusted earnings - the market is pricing in successful execution of the portfolio reshaping and continued mid-single-digit growth, not a bargain. If DuPont hits the raised $7.17-$7.32 guidance and grows EPS around 10% into 2027, the multiple is sustainable and the stock can grind toward the Street's $168-$172 targets. If growth stalls at ~4% or PFAS expenses escalate, the multiple could revert toward 15-16x, implying $110-$120. The asymmetry is modestly positive but not compelling.

As of 2026-08-27, the 14-day RSI stands at 47.46 (neutral, no overbought/oversold edge). Price is 1.69% below the 20-day SMA, 0.33% below the 50-day SMA, and 1.85% above the 200-day SMA - a range-bound consolidation roughly 12% below the 52-week high of $157.98 and about 50% above the 52-week low of $92.49. There is no fresh breakout or capitulation signal; entry timing is neutral rather than compelling.

• Specialty-chemicals destocking cycle has largely abated; end-market recovery is underway in aerospace, biopharma, EV components, and industrial water treatment.
• Secular growth in municipal water scarcity and cleanroom/semiconductor infrastructure supports the Healthcare & Water Technologies core.
• PFAS / 'forever chemicals' regulatory and litigation overhang - the July 2026 NY AG lawsuit seeks cleanup funding and consumer warnings.
• Interest rates and risk appetite: with beta of 1.09, DD's forward multiple is sensitive to the cost of capital and industrial capex sentiment.
• Ongoing post-spinoff identity shift - smaller revenue base, reverse-split share count, revised index positions - changes how the market benchmarks and values the stock.

• Q3 2026 earnings release on November 5, 2026 - confirmation that H2 growth accelerates as guidance implies.
• Execution of the $250M Q3 2026 share repurchase program and Any further capital-return announcements.
• PFAS litigation developments - a manageable settlement or court narrowing of liability would remove the biggest valuation overhang.
• Commercial win momentum in water treatment (MemCor membrane contract in Canberra) and cleanroom products (Tyvek expansion).

• PFAS liability expansion - the New York AG lawsuit (July 2026) and potential follow-on litigation/cleanup costs are open-ended.
• Rich valuation versus DuPont's own history (~19x forward vs 14.6x 5-year average) leaves no cushion if adjusted EPS guidance is missed.
• Modest organic growth (~4%) means any macro slowdown in biopharma, aerospace, or industrial water could stall the re-rating.
• Post-split/divestiture transition risk - reverse-split mechanics, stale analyst targets, and estimate resets can add volatility.

DuPont's remaining business is materially better than the backward-looking headline numbers suggest: Q2 was a beat-and-raise, the balance sheet is conservative (debt-to-equity 0.23, current ratio 2.4), FCF conversion is strong, and exposure to water treatment, biopharma, and cleanroom demand is secular. But at roughly 19x forward earnings the stock is fairly to modestly richly valued with an unresolved PFAS overhang - a cautious bullish stance for long-term holders, but accumulation near $125-$130 is more attractive than chasing $138.83.

Applied a 20x justified forward P/E to management's raised 2026 adjusted EPS guidance midpoint of $7.25 (20 × $7.25 = $145.00). The 20x multiple is a premium to DuPont's 14.6x 5-year average, justified by the higher-margin, lower-debt post-divestiture portfolio and >100% FCF conversion, but a deliberate discount to the Street's $168-$172 targets (which imply ~23x) to account for the open-ended PFAS liability and mid-single-digit organic growth ceiling.